Adalimumab-afzb Injection
Brand names: Abrilada
Category: Rheumatology
FDA status: To Be Discontinued · Last FDA update: Oct 9, 2025 · First posted: Oct 9, 2025 · 1 manufacturers, 1 listed presentations
As of Oct 9, 2025, the FDA lists Adalimumab-afzb Injection as being discontinued. Of 1 manufacturer presentations, 1 Not specified.
| Presentation & package NDC | Manufacturer | Availability | FDA note |
|---|---|---|---|
| Abrilada, Injection, Kit (NDC 0025-0325-01) NDC 0025-0325-01 |
Pfizer Inc. | Not specified | Discontinuation of the manufacture of the drug |
Related medications in shortage
Other Rheumatology medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.
Change log
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.
Cite this: “FDA drug-shortage status for Adalimumab-afzb Injection (FDA data as of Oct 9, 2025). Shortage Watch, openFDA.”
Get an email when this record changes
One email, only when the FDA changes something for Adalimumab-afzb Injection. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.
Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.
Embed a live status badge: /badge/adalimumab-afzb-injection.svg
FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).